product name Flubendazole
Description: Flubendazole (also known as Flumoxanal, NSC 313680) is an autophagy inducer by targeting Atg4B, it is used to treat internal parasite and worm infection. Flubendazole results in morphological changes included contraction of the soma region, formation of blebs on the tegument, rostellar disorganization, loss of hooks and destruction of microtriches in Echinococcus granulosus.
References: Parasitol Res. 2006 Mar;98(4):317-23.
313.28
Formula
C16H12FN3O3
CAS No.
31430-15-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 3 mg/mL (9.6 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
Flumoxanal, NSC 313680
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19396060
| In Vitro |
In vitro activity: Flubendazole results in morphological changes included contraction of the soma region, formation of blebs on the tegument, rostellar disorganization, loss of hooks and destruction of microtriches in Echinococcus granulosus. Flubendazole have a bicyclic ring system in which a benzene has been fused to the -4 and -5 positions of the heterocycle (imidazole). Flubendazole and Albendazole shows similar potency in affecting rat embryonic development in vitro, inducing retardation of growth and dysmorphogenic effects at concentrations ≥0.5 μg/mL. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Flubendazole (6.32 mg/kg/day) initially induces an arrest of embryonic development followed by a generalized cell death that leads to 100% embryolethality by gestation day (GD) 12.5. Flubendazole (3.46 mg/kg/day) markedly reduces embryonic development by GD 12.5 without causing cell death. Flubendazole in olive oil causes a statistically significant increase in embryolethality at doses of 7.83 mg/kg per day and higher, with complete resorption in all dams at 31.33 mg/kg per day in rats. Flubendazole treatment causes a slight increase of metyrapone and daunorubicin activities in hepatic as well as intestinal cytosol in birds. Flubendazole treatment leads to statistically significant inhibition of intestinal GST activity. Flubendazole treatment leads to slight but significant inhibition (decrease to 69%) of 7-ethoxyresorufin activity in hepatic microsomes. |
| Animal model | |
| Formulation & Dosage | |
| References | Parasitol Res. 2006 Mar;98(4):317-23; Reprod Toxicol. 2014 Nov;49:33-42. |
Related Posts
product name Flubendazole
Description: Flubendazole (also known as Flumoxanal, NSC 313680) is an autophagy inducer by targeting Atg4B, it is used to treat internal parasite and worm infection. Flubendazole results in morphological changes included contraction of the soma region, formation of blebs on the tegument, rostellar disorganization, loss of hooks and destruction of microtriches in Echinococcus granulosus.
References: Parasitol Res. 2006 Mar;98(4):317-23.
313.28
Formula
C16H12FN3O3
CAS No.
31430-15-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 3 mg/mL (9.6 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
Flumoxanal, NSC 313680
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19396060
| In Vitro |
In vitro activity: Flubendazole results in morphological changes included contraction of the soma region, formation of blebs on the tegument, rostellar disorganization, loss of hooks and destruction of microtriches in Echinococcus granulosus. Flubendazole have a bicyclic ring system in which a benzene has been fused to the -4 and -5 positions of the heterocycle (imidazole). Flubendazole and Albendazole shows similar potency in affecting rat embryonic development in vitro, inducing retardation of growth and dysmorphogenic effects at concentrations ≥0.5 μg/mL. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Flubendazole (6.32 mg/kg/day) initially induces an arrest of embryonic development followed by a generalized cell death that leads to 100% embryolethality by gestation day (GD) 12.5. Flubendazole (3.46 mg/kg/day) markedly reduces embryonic development by GD 12.5 without causing cell death. Flubendazole in olive oil causes a statistically significant increase in embryolethality at doses of 7.83 mg/kg per day and higher, with complete resorption in all dams at 31.33 mg/kg per day in rats. Flubendazole treatment causes a slight increase of metyrapone and daunorubicin activities in hepatic as well as intestinal cytosol in birds. Flubendazole treatment leads to statistically significant inhibition of intestinal GST activity. Flubendazole treatment leads to slight but significant inhibition (decrease to 69%) of 7-ethoxyresorufin activity in hepatic microsomes. |
| Animal model | |
| Formulation & Dosage | |
| References | Parasitol Res. 2006 Mar;98(4):317-23; Reprod Toxicol. 2014 Nov;49:33-42. |